HRP20202025T1 - Kondenzirani derivati tiofena korisni kao inhibitori napi-iib - Google Patents
Kondenzirani derivati tiofena korisni kao inhibitori napi-iib Download PDFInfo
- Publication number
- HRP20202025T1 HRP20202025T1 HRP20202025TT HRP20202025T HRP20202025T1 HR P20202025 T1 HRP20202025 T1 HR P20202025T1 HR P20202025T T HRP20202025T T HR P20202025TT HR P20202025 T HRP20202025 T HR P20202025T HR P20202025 T1 HRP20202025 T1 HR P20202025T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- image
- pharmaceutically acceptable
- compound according
- acceptable salt
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003577 thiophenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- AMOHQOVBWMGTAS-UHFFFAOYSA-N 4-[2-[2,6-difluoro-4-[[2-[[3-[[4-(4-hydroxybutylcarbamoyl)-2,2-dimethylpiperazin-1-yl]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonyl]amino]phenyl]ethyl]benzoic acid Chemical compound FC1=C(C(=CC(=C1)NC(=O)C1=C(SC2=C1CCCC2)NC(C1=CC(=CC=C1)CN1C(CN(CC1)C(NCCCCO)=O)(C)C)=O)F)CCC1=CC=C(C(=O)O)C=C1 AMOHQOVBWMGTAS-UHFFFAOYSA-N 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- AKSLXDVWYUQVED-UHFFFAOYSA-N 4-[2-[2,6-difluoro-4-[[2-[[3-[[4-(3-hydroxypropyl)-2,2-dimethylpiperazin-1-yl]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonyl]amino]phenyl]ethyl]benzoic acid Chemical compound FC1=C(C(=CC(=C1)NC(=O)C1=C(SC2=C1CCCC2)NC(C1=CC(=CC=C1)CN1C(CN(CC1)CCCO)(C)C)=O)F)CCC1=CC=C(C(=O)O)C=C1 AKSLXDVWYUQVED-UHFFFAOYSA-N 0.000 claims 1
- RHSJYHIKJJCPIW-UHFFFAOYSA-N 4-[2-[2,6-difluoro-4-[[2-[[3-[[4-(3-methoxypropyl)-2,2-dimethylpiperazin-1-yl]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonyl]amino]phenyl]ethyl]benzoic acid Chemical compound FC1=C(C(=CC(=C1)NC(=O)C1=C(SC2=C1CCCC2)NC(C1=CC(=CC=C1)CN1C(CN(CC1)CCCOC)(C)C)=O)F)CCC1=CC=C(C(=O)O)C=C1 RHSJYHIKJJCPIW-UHFFFAOYSA-N 0.000 claims 1
- BCJPSDBOYKYMSF-UHFFFAOYSA-N 4-[2-[2,6-difluoro-4-[[2-[[3-[[4-(4-methoxybutylcarbamoyl)-2,2-dimethylpiperazin-1-yl]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonyl]amino]phenyl]ethyl]benzoic acid Chemical compound FC1=C(C(=CC(=C1)NC(=O)C1=C(SC2=C1CCCC2)NC(C1=CC(=CC=C1)CN1C(CN(CC1)C(NCCCCOC)=O)(C)C)=O)F)CCC1=CC=C(C(=O)O)C=C1 BCJPSDBOYKYMSF-UHFFFAOYSA-N 0.000 claims 1
- NMVJBGKJMHBVKZ-UHFFFAOYSA-N 4-[2-[4-[[2-[[3-[[4-(2-aminoacetyl)-2,2-dimethylpiperazin-1-yl]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonyl]amino]-2,6-difluorophenyl]ethyl]benzoic acid Chemical compound NCC(=O)N1CC(N(CC1)CC=1C=C(C(=O)NC=2SC3=C(C=2C(=O)NC2=CC(=C(C(=C2)F)CCC2=CC=C(C(=O)O)C=C2)F)CCCC3)C=CC=1)(C)C NMVJBGKJMHBVKZ-UHFFFAOYSA-N 0.000 claims 1
- ZUGOIDVRXVSTGB-UHFFFAOYSA-N 4-[2-[4-[[2-[[3-[[4-(3-carboxypropyl)-2,2-dimethylpiperazin-1-yl]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonyl]amino]-2,6-difluorophenyl]ethyl]benzoic acid Chemical compound C(=O)(O)CCCN1CC(N(CC1)CC=1C=C(C(=O)NC=2SC3=C(C=2C(=O)NC2=CC(=C(C(=C2)F)CCC2=CC=C(C(=O)O)C=C2)F)CCCC3)C=CC=1)(C)C ZUGOIDVRXVSTGB-UHFFFAOYSA-N 0.000 claims 1
- WQTHFTPQJHKPOV-UHFFFAOYSA-N 4-[2-[4-[[2-[[3-[[4-[bis(2-methoxyethyl)sulfamoyl]-2,2-dimethylpiperazin-1-yl]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonyl]amino]-2,6-difluorophenyl]ethyl]benzoic acid Chemical compound COCCN(S(=O)(=O)N1CC(N(CC1)CC=1C=C(C(=O)NC=2SC3=C(C=2C(=O)NC2=CC(=C(C(=C2)F)CCC2=CC=C(C(=O)O)C=C2)F)CCCC3)C=CC=1)(C)C)CCOC WQTHFTPQJHKPOV-UHFFFAOYSA-N 0.000 claims 1
- DKRYMIXKYUMEFF-UHFFFAOYSA-N 4-[4-[[3-[[3-[[4-[2-(4-carbamoylphenyl)ethyl]-3,5-difluorophenyl]carbamoyl]-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]phenyl]methyl]-3,3-dimethylpiperazin-1-yl]-4-oxobutanoic acid Chemical compound C(N)(=O)C1=CC=C(C=C1)CCC1=C(C=C(C=C1F)NC(=O)C1=C(SC2=C1CCCC2)NC(=O)C=1C=C(C=CC=1)CN1C(CN(CC1)C(CCC(=O)O)=O)(C)C)F DKRYMIXKYUMEFF-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000007962 solid dispersion Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940117958 vinyl acetate Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Claims (18)
1. Spoj formule:
[image]
,
naznačen time što
Y je kondenzirani cikloheksanski prsten ili kondenzirani fenilni prsten,
gdje je A
[image]
ili
[image]
,
gdje prekrižene linije prikazuju veze za mjesto vezanja na jezgru Formule II, a isprekidane linije prikazuju veze za mjesto vezanja na R2,
gdje se R2 bira iz skupine koju čine -CH3, -(CH2)3OH, -(CH2)3OCH3, -(CH2)3CO2H, -COOCH3, -COCH3, -CO(CH2)3CH3, -COCH(CH3)2, -CO(CH2)2CO2H, -COCH2NH2, -COCH2N(CH3)2, -SO2N[(CH2)2OCH3]2, -SO2NHCH3, -SO2(CH2)2OCH3, -CONH(CH2)4OH, -CONH(CH2)4OCH3, -CONHCH3, -CONH(CH2)2CO2H, -CONH(CH2)2OCH3, -CON(CH2CH2OCH3)2, -CSNHCH3,
[image]
,
[image]
, te
[image]
,
gdje isprekidane linije predstavljaju mjesto vezanja, gdje je R’ -CO2H ili -CONH2;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Y kondenzirani cikloheksanski prsten, A je
[image]
,
a R’ je -CO2H;
ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima formulu:
[image]
,
gdje se R2 bira iz skupine koju čine -(CH2)3OH, -(CH2)3OCH3, -(CH2)3CO2H, -CONH(CH2)4OH, -COCH2NH2, -SO2N[(CH2)2OCH3]2, -CONH(CH2)4OCH3, te -CO(CH2)2CO2H,
gdje je R’ -CO2H ili -CONH2;
ili njegova farmaceutski prihvatljiva sol.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R’ -CO2H, ili njegova farmaceutski prihvatljiva sol.
5. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[2-[2,6-difluor-4-[[2-[[3-[[4-(4-hidroksibutilkarbamoil)-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]fenil]etil]benzojeva kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što je 4-[2-[2,6-difluor-4-[[2-[[3-[[4-(4-hidroksibutilkarbamoil)-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]fenil]etil]benzojeva kiselina, disodium.
7. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[2-[2,6-difluor-4-[[2-[[3-[[4-(3-hidroksipropil)-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]fenil]etil]benzojeva kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
8. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[2-[4-[[2-[[3-[[4-[bis(2-metoksietil)sulfamoil]-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]-2,6-difluorfenil]etil]benzojeva kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
9. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[2-[4-[[2-[[3-[[4-(3-karboksipropil)-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]-2,6-difluorfenil]etil]benzojeva kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
10. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[2-[2,6-difluor-4-[[2-[[3-[[4-(3-metoksipropil)-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]fenil]etil]benzojeva kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
11. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[2-[4-[[2-[[3-[[4-(2-aminoacetil)-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]-2,6-difluorfenil]etil]benzojeva kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
12. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[2-[2,6-difluor-4-[[2-[[3-[[4-(4-metoksibutilkarbamoil)-2,2-dimetilpiperazin-1-il]metil]benzoil]amino]-4,5,6,7-tetrahidrobenzotiofen-3-karbonil]amino]fenil]etil]benzojeva kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
13. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što je 4-[4-[[3-[[3-[[4-[2-(4-karbamoilfenil)etil]-3,5-difluorfenil]karbamoil]-4,5,6,7-tetrahidrobenzotiofen-2-il]karbamoil]fenil]metil]-3,3-dimetilpiperazin-1-il]-4-oksobutanska kiselina, koju se može strukturno prikazati kao:
[image]
,
ili njezina farmaceutski prihvatljiva sol.
14. Farmaceutski pripravak, naznačen time što sadrži spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 13, kao i farmaceutski prihvatljivi nosač, razrjeđivač ili pomoćno sredstvo.
15. Formulacija u obliku čvrste disperzije, naznačena time što sadrži 30% spoja u skladu s patentnim zahtjevom 6 i 70% polivinilpirolidon–vinil-acetata.
16. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je namijenjen upotrebi u terapiji.
17. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je namijenjen upotrebi u liječenju hiperfosfatemije.
18. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je namijenjen upotrebi u liječenju kronične bolesti bubrega ili kardiovaskularne bolesti povezane s kroničnom bolesti bubrega.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662375169P | 2016-08-15 | 2016-08-15 | |
| PCT/US2017/045843 WO2018034883A1 (en) | 2016-08-15 | 2017-08-08 | Condensed thiophene derivatives useful as napi-iib inhibitors |
| EP17754914.4A EP3497091B1 (en) | 2016-08-15 | 2017-08-08 | Condensed thiophene derivatives useful as napi-iib inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20202025T1 true HRP20202025T1 (hr) | 2021-02-19 |
Family
ID=59677343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202025TT HRP20202025T1 (hr) | 2016-08-15 | 2020-12-17 | Kondenzirani derivati tiofena korisni kao inhibitori napi-iib |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10934280B2 (hr) |
| EP (1) | EP3497091B1 (hr) |
| JP (1) | JP6653410B2 (hr) |
| KR (1) | KR102266143B1 (hr) |
| CN (1) | CN109563070B (hr) |
| AU (1) | AU2017312783B2 (hr) |
| BR (1) | BR112019000929A2 (hr) |
| CA (1) | CA3033628C (hr) |
| CY (1) | CY1123576T1 (hr) |
| DK (1) | DK3497091T3 (hr) |
| EA (1) | EA037376B1 (hr) |
| ES (1) | ES2830444T3 (hr) |
| HR (1) | HRP20202025T1 (hr) |
| HU (1) | HUE052351T2 (hr) |
| IL (1) | IL264785B (hr) |
| LT (1) | LT3497091T (hr) |
| MX (1) | MX2019001781A (hr) |
| PL (1) | PL3497091T3 (hr) |
| PT (1) | PT3497091T (hr) |
| RS (1) | RS61165B1 (hr) |
| SA (1) | SA519401049B1 (hr) |
| SI (1) | SI3497091T1 (hr) |
| WO (1) | WO2018034883A1 (hr) |
| ZA (1) | ZA201900305B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202105190SA (en) * | 2018-11-19 | 2021-06-29 | 11949098 Canada Inc | 4,5,6,7-tetrahydro-l-benzothiophene modulators of retinoic acid receptor related (rar) orphan nuclear receptors (rors) |
| CN113784956A (zh) * | 2019-05-16 | 2021-12-10 | 伊莱利利公司 | 钠-氢交换体3抑制剂化合物 |
| AU2022288895A1 (en) | 2021-06-08 | 2024-01-18 | Chugai Seiyaku Kabushiki Kaisha | Formulation containing dihydropyridazine-3,5-dione derivative |
| AR126060A1 (es) | 2021-06-08 | 2023-09-06 | Chugai Pharmaceutical Co Ltd | Método para producir derivado de dihidropiridazin-3,5-diona |
| WO2023219127A1 (ja) * | 2022-05-11 | 2023-11-16 | 中外製薬株式会社 | 嚢胞性疾患を治療または予防するための医薬組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2565190E (pt) * | 2010-04-28 | 2015-08-24 | Astellas Pharma Inc | Composto de tetra-hidrobenzotiofeno |
| JP6020460B2 (ja) * | 2011-10-27 | 2016-11-02 | アステラス製薬株式会社 | アミノアルキル置換ｎ−チエニルベンズアミド誘導体 |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| CN105658635B (zh) * | 2014-08-22 | 2019-03-08 | 江苏恒瑞医药股份有限公司 | 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用 |
-
2017
- 2017-08-08 EA EA201990095A patent/EA037376B1/ru not_active IP Right Cessation
- 2017-08-08 RS RS20201471A patent/RS61165B1/sr unknown
- 2017-08-08 WO PCT/US2017/045843 patent/WO2018034883A1/en unknown
- 2017-08-08 BR BR112019000929A patent/BR112019000929A2/pt active Search and Examination
- 2017-08-08 EP EP17754914.4A patent/EP3497091B1/en active Active
- 2017-08-08 US US16/321,575 patent/US10934280B2/en active Active
- 2017-08-08 KR KR1020197004106A patent/KR102266143B1/ko active IP Right Grant
- 2017-08-08 PL PL17754914T patent/PL3497091T3/pl unknown
- 2017-08-08 MX MX2019001781A patent/MX2019001781A/es active IP Right Grant
- 2017-08-08 CN CN201780049441.2A patent/CN109563070B/zh active Active
- 2017-08-08 ES ES17754914T patent/ES2830444T3/es active Active
- 2017-08-08 LT LTEP17754914.4T patent/LT3497091T/lt unknown
- 2017-08-08 AU AU2017312783A patent/AU2017312783B2/en active Active
- 2017-08-08 JP JP2019527785A patent/JP6653410B2/ja active Active
- 2017-08-08 SI SI201730453T patent/SI3497091T1/sl unknown
- 2017-08-08 PT PT177549144T patent/PT3497091T/pt unknown
- 2017-08-08 DK DK17754914.4T patent/DK3497091T3/da active
- 2017-08-08 HU HUE17754914A patent/HUE052351T2/hu unknown
- 2017-08-08 CA CA3033628A patent/CA3033628C/en active Active
-
2019
- 2019-01-16 ZA ZA2019/00305A patent/ZA201900305B/en unknown
- 2019-02-07 SA SA519401049A patent/SA519401049B1/ar unknown
- 2019-02-11 IL IL264785A patent/IL264785B/en active IP Right Grant
-
2020
- 2020-11-16 CY CY20201101084T patent/CY1123576T1/el unknown
- 2020-12-17 HR HRP20202025TT patent/HRP20202025T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190026895A (ko) | 2019-03-13 |
| EA201990095A1 (ru) | 2019-07-31 |
| JP6653410B2 (ja) | 2020-02-26 |
| PT3497091T (pt) | 2020-11-30 |
| SI3497091T1 (sl) | 2020-11-30 |
| AU2017312783A1 (en) | 2019-01-24 |
| US20200031813A1 (en) | 2020-01-30 |
| HUE052351T2 (hu) | 2021-04-28 |
| CA3033628A1 (en) | 2018-02-22 |
| PL3497091T3 (pl) | 2021-02-08 |
| KR102266143B1 (ko) | 2021-06-17 |
| MX2019001781A (es) | 2019-07-04 |
| IL264785B (en) | 2021-04-29 |
| EP3497091A1 (en) | 2019-06-19 |
| CY1123576T1 (el) | 2022-03-24 |
| NZ750153A (en) | 2021-01-29 |
| SA519401049B1 (ar) | 2021-07-14 |
| CA3033628C (en) | 2021-01-12 |
| EA037376B1 (ru) | 2021-03-22 |
| RS61165B1 (sr) | 2021-01-29 |
| CN109563070A (zh) | 2019-04-02 |
| DK3497091T3 (da) | 2020-10-19 |
| CN109563070B (zh) | 2021-02-26 |
| AU2017312783B2 (en) | 2020-02-06 |
| WO2018034883A1 (en) | 2018-02-22 |
| ZA201900305B (en) | 2020-12-23 |
| ES2830444T3 (es) | 2021-06-03 |
| JP2019527734A (ja) | 2019-10-03 |
| EP3497091B1 (en) | 2020-10-07 |
| LT3497091T (lt) | 2020-12-28 |
| BR112019000929A2 (pt) | 2019-07-09 |
| US10934280B2 (en) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202025T1 (hr) | Kondenzirani derivati tiofena korisni kao inhibitori napi-iib | |
| HRP20201304T1 (hr) | Spoj derivata 1,3,4-oksadiazol-amida koji služi kao inhibitor histonske deacetilaze 6 i farmaceutski pripravak koji sadrži taj spoj | |
| HRP20201934T1 (hr) | Anti-fibrotički piridinoni | |
| HRP20200341T1 (hr) | Bromodomenski (bet) inhibitori | |
| HRP20230090T1 (hr) | Heterociklički spojevi kao imunomodulatori | |
| HRP20160967T1 (hr) | Heterociklički spojevi korisni kao pdk1 inhibitori | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| HRP20220003T1 (hr) | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| HRP20171258T1 (hr) | Acilamino-supstituirani kondenzirani derivati ciklopentankarboksilne kiseline i njihova upotreba kao farmaceutski proizvodi | |
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| HRP20171122T1 (hr) | Novi makrociklusi kao inhibitori faktora xia | |
| AR048334A1 (es) | Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta. | |
| HRP20170307T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA | |
| HRP20170784T1 (hr) | Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora | |
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| HRP20140950T1 (hr) | Novi spojevi i pripravci, te postupci njihove primjene | |
| HRP20151386T1 (hr) | Fenil aminopirimidinski spojevi i njihova primjena | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| HRP20230162T1 (hr) | Heteroarilni inhibitori enzima pde4 | |
| JP2017526636A5 (hr) | ||
| AR035676A1 (es) | Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
| RS54824B1 (sr) | Topikalna formulacija za inhibiciju jak-a | |
| JP2010517946A5 (hr) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| RU2010119645A (ru) | Замещенные гетероциклом пиперазинодигидротиенопиримидины |